KDR and neuroendocrine carcinoma: There are ongoing trials of agents targeting angiogenic molecules in cancers, including GEP-NECs: a phase II trial of bevacizumab plus nab-paclitaxel in NEC (NCT04705519), a phase II trial of multi-targeted TKI (mainly targeting VEGFRs and PDGFRs), anlotinib in G3 GEP-NET including NEC (NCT03457844), and a phase II trial of cabozantinib targeting VEGFR2/MET proto-oncogene/AXL in G3 NENs including NEC (NCT04412629) (Table 7 and Fig. 2).